[{"orgOrder":0,"company":"Future Pak","sponsor":"Theratechnologies","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Antibody, Unconjugated","year":"2025","type":"Acquisition","leadProduct":"Ibalizumab","moa":"T-cell surface antigen CD4","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Future Pak","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Future Pak \/ Future Pak","highestDevelopmentStatusID":"15","companyTruncated":"Future Pak \/ Future Pak"}]

Find Clinical Drug Pipeline Developments & Deals by Future Pak

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : Trogarzo (ibalizumab) is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors.

                          Product Name : Trogarzo

                          Product Type : Antibody, Unconjugated

                          Upfront Cash : Undisclosed

                          September 25, 2025

                          Lead Product(s) : Ibalizumab

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Approved FDF

                          Recipient : Theratechnologies

                          Deal Size : Undisclosed

                          Deal Type : Acquisition

                          blank